Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 1.0.0-ballot3 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions
| Official URL: https://fevir.net/resources/Evidence/236987 | Version: 1.0.0-ballot3 | ||||
| Standards status: Informative | Computable Name: Body_weight_from_MAGICapp_109588 | ||||
| Other Identifiers: FEvIR Object Identifier: FEvIR Object Identifier#236987, outcomeId: 109588, picoId: 85798, sectionId: 73215, OID:2.16.840.1.113883.4.642.40.44.22.150 | |||||
Usage: Evidence Communication: ComparativeEvidence |
|||||
Copyright/Legal: Copyright the Authors else Computable Publishing LLC. Noncommercial use permitted with CC BY-NC-SA 4.0 (https://creativecommons.org/licenses/by-nc-sa/4.0/). Commercial use permitted as agreed in Terms of Use (https://fevir.net/termsofuse). |
|||||
This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide.
version: 72; Last updated: 2026-08-06 17:15:59+0000
Profile: ComparativeEvidence
ArtifactPublicationStatus: Active
identifier: FEvIR Object Identifier/236987, outcomeId/109588, picoId/85798, sectionId/73215, Uniform Resource Identifier (URI)/urn:oid:2.16.840.1.113883.4.642.40.44.22.150
version: 1.0.0-ballot3
name: Body_weight_from_MAGICapp_109588
title: MAGIC-derived Evidence: Body weight with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
citeAs:
MAGIC-derived Evidence: Body weight with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 236987. Revised 2026-08-06. Available at: https://fevir.net/resources/Evidence/236987. Computable resource at: https://fevir.net/resources/Evidence/236987#json.
status: Active
date: 2026-11-05 14:34:28+0000
author: Computable Publishing®: MAGIC-to-FEvIR Converter:
publisher: HL7 International / Clinical Decision Support
contact: HL7 International / Clinical Decision Support: http://www.hl7.org/Special/committees/dss
| Code | Value[x] |
| Evidence Based Medicine on FHIR Implementation Guide Code System: evidence-communication (Evidence Communication) | ComparativeEvidence |
copyright:
Copyright the Authors else Computable Publishing LLC. Noncommercial use permitted with CC BY-NC-SA 4.0 (https://creativecommons.org/licenses/by-nc-sa/4.0/). Commercial use permitted as agreed in Terms of Use (https://fevir.net/termsofuse).
| Type | Target[x] |
| Part Of | MAGICapp Conversion Report: SGLT2 inhibitors and GLP-1 RA for type 2 diabetes (Identifier: FEvIR Linking Identifier/MAGIC-5288-j1Wqrn-conversion-report) |
description:
This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide.
assertion:
SGLT2 inhibitors probably reduce body weight compared with GLP-1 receptor agonists.
variableDefinition
description:
Adults with type 2 diabetes
variableRole: Population
variableDefinition
description:
GroupAssignment: SGLT2 inhibitors vs. GLP-1 RA
variableRole: Exposure
comparatorCategory: GLP-1 RA
variableDefinition
description:
Body weight
variableRole: Outcome
observed: Body weight
synthesisType: SYSTEMATIC_REVIEW
studyDesign: NOTSET
statistic
description:
MD -0.47 Kg (CI95 -0.09 Kg to -0.85 Kg)
statisticType: difference in means
quantity: -0.47 Kg
SampleSizes
NumberOfStudies NumberOfParticipants 2 1139 AttributeEstimates
Type Range CI95 -0.09--0.85 Kg
certainty
description:
Due to serious inconsistency
type: Overall certainty
rating: Moderate certainty
Subcomponents
Type Rating Risk of Bias NOTSET Inconsistency SERIOUS Indirectness NOTSET Imprecision NOTSET Publication Bias NOTSET